ADAM17 and COVID-19: Two ADAM17 inhibitors have been tested in animal models of COVID-19, apratastat (TMI-005) and TMI-1, resulting in a significant reduction in the production of pro-inflammatory cytokines as well as in protective effects against lung injury associated with COVID-19 [122].